Achieving remission of proteinuria in childhood CKD

[1]  G. Remuzzi,et al.  Progression, Remission and Regression of Chronic Renal Diseases , 2016, Nephron.

[2]  G. Remuzzi,et al.  Regression of Renal Disease by Angiotensin II Antagonism Is Caused by Regeneration of Kidney Vasculature. , 2016, Journal of the American Society of Nephrology.

[3]  G. Remuzzi,et al.  A Multidrug, Antiproteinuric Approach to Alport Syndrome: A Ten-Year Cohort Study , 2015, Nephron.

[4]  P. Peduzzi,et al.  Combined angiotensin inhibition for the treatment of diabetic nephropathy. , 2013, The New England journal of medicine.

[5]  H. Pan,et al.  Standardizing Anthropometric Measures in Children and Adolescents with Functions for Egen: Update , 2013 .

[6]  S. Shahinfar,et al.  Losartan and enalapril are comparable in reducing proteinuria in children with Alport syndrome , 2013, Pediatric Nephrology.

[7]  Nish Chaturvedi,et al.  Cardiorenal end points in a trial of aliskiren for type 2 diabetes. , 2012, The New England journal of medicine.

[8]  G. Remuzzi,et al.  Mechanisms and treatment of CKD. , 2012, Journal of the American Society of Nephrology : JASN.

[9]  S. Shahinfar,et al.  Losartan and enalapril are comparable in reducing proteinuria in children. , 2012, Kidney international.

[10]  G. Remuzzi,et al.  Proteinuria should be used as a surrogate in CKD , 2012, Nature Reviews Nephrology.

[11]  Harvey Goldstein,et al.  REALCOM-IMPUTE Software for Multilevel Multiple Imputation with Mixed Response Types , 2011 .

[12]  Remission Clinic Task Force.  The Remission Clinic approach to halt the progression of kidney disease. , 2011, Journal of nephrology.

[13]  J. Ingelfinger.  Blood-pressure control and delay in progression of kidney disease in children. , 2009, The New England journal of medicine.

[14]  A. Anarat,et al.  Strict blood-pressure control and progression of renal failure in children. , 2009, The New England journal of medicine.

[15]  G. Remuzzi,et al.  Proteinuria: Is the ONTARGET renal substudy actually off target? , 2009, Nature Reviews Nephrology.

[16]  G. Remuzzi,et al.  Proteinuria: Increased angiotensin-receptor blocking is not the first option , 2009, Nature Reviews Nephrology.

[17]  E. Burgess,et al.  Supramaximal dose of candesartan in proteinuric renal disease. , 2009, Journal of the American Society of Nephrology : JASN.

[18]  Susan L Furth,et al.  New equations to estimate GFR in children with CKD. , 2009, Journal of the American Society of Nephrology : JASN.

[19]  G. Remuzzi,et al.  Angiotensin converting enzyme insertion/deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathies. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[20]  G. Remuzzi,et al.  Role of remission clinics in the longitudinal treatment of CKD. , 2008, Journal of the American Society of Nephrology : JASN.

[21]  S. Yusuf,et al.  Telmisartan, ramipril, or both in patients at high risk for vascular events. , 2008, The New England journal of medicine.

[22]  Jing Cheng-xue.  Epidemiology of Chronic Kidney Disease in Children , 2008 .

[23]  M. Panteghini.  Enzymatic assays for creatinine: time for action. , 2008, Clinical chemistry and laboratory medicine.

[24]  A. Bomback,et al.  The incidence and implications of aldosterone breakthrough , 2007, Nature Clinical Practice Nephrology.

[25]  G. Remuzzi,et al.  Time to abandon microalbuminuria? , 2006, Kidney international.

[26]  Wilfried De Backer,et al.  Body surface area in normal-weight, overweight, and obese adults. A comparison study. , 2006, Metabolism: clinical and experimental.

[27]  G. Remuzzi,et al.  ACE inhibition reduces glomerulosclerosis and regenerates glomerular tissue in a model of progressive renal disease. , 2006, Kidney international.

[28]  G. Remuzzi,et al.  Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. , 2003, Kidney international.

[29]  G. Remuzzi,et al.  Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. , 2003, Kidney international.

[30]  B. Brenner,et al.  Remission Achieved in Chronic Nephropathy by a Multidrug Approach Targeted at Urinary Protein Excretion , 2001, Nephron.

[31]  G. Remuzzi,et al.  Progression, remission, regression of chronic renal diseases , 2001, The Lancet.

[32]  Teven,et al.  EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN TYPE 2 DIABETES AND NEPHROPATHY EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND NEPHROPATHY , 2001 .

[33]  G. Remuzzi,et al.  Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial , 1998, The Lancet.

[34]  P. Ruggenetu.  Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril : REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN) , 1998 .

[35]  G. Ruocco,et al.  Angiotensin converting enzyme inhibitors and reflux nephropathy: 2-year follow-up , 1997, Pediatric Nephrology.

[36]  T. Greene,et al.  Blood Pressure Control, Proteinuria, and the Progression of Renal Disease , 1995, Annals of Internal Medicine.

[37]  T. Greene,et al.  Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. , 1995, Annals of internal medicine.

[38]  H. Trachtman,et al.  Effect of angiotensin-converting enzyme inhibitor therapy on proteinuria in children with renal disease. , 1988, The Journal of pediatrics.

[39]  S. Poucell,et al.  Focal segmental glomerulosclerosis with idiopathic nephrotic syndrome: three types of clinical response. , 1982, The Journal of pediatrics.